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Abstract
Background: As HIV-specific cytotoxic T cells play a key role during acute and chronic HIV-1
infection in humans, the ability of potential anti-HIV vaccines to elicit strong, broad T cell responses
is likely to be crucial. The HIV-1 Gag antigen is widely considered a relevant antigen for the
development of an anti-HIV vaccine since it is one of the most conserved viral proteins and is also
known to induce T cell responses. In the majority of studies reporting Gag-specific cellular immune
responses induced by Gag-based vaccines, only a small number of Gag T cell epitopes were tested
in preclinical mouse models, thus giving an incomplete picture of the numerous possible cellular
immune responses against this antigen. As is, this partial knowledge of epitope-specific T cell
responses directed to Gag will unavoidably result in a limited preclinical evaluation of Gag-based
vaccines.
Results: In this study we identified new Gag CD8+ T cell epitopes in BALB/c mice vaccinated with
the HIV-1 Gag antigen alone or in combination with the HIV-1 Tat protein, which was recently
shown to broaden T cell responses directed to Gag. Specifically, we found that CTL responses to
Gag may be directed to nine different CTL epitopes, and four of these were mapped as minimal
CTL epitopes.
Conclusion: These newly identified CTL epitopes should be considered in the preclinical
evaluation of T cell responses induced by Gag-based vaccines in mice.
Background
Cellular immune responses are a critical part of the host
defence against viruses, with cytotoxic T lymphocytes
(CTLs) playing a key role in recognizing and eliminating
infected cells. CTLs identify their targets as 8–10 amino
acid long peptides which are derived from the intracellu-
lar degradation of viral antigens and presented in associa-
tion with major histocompatibility complex class I (MHC-
I) molecules at the surface of infected cells [1-3].
Several studies have indicated that HIV-specific T cell
responses play a key role in limiting the progression of
acute and chronic infection in humans [4,5], and that
long-term non-progressors have consistently higher levels
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the ability of potential vaccines for HIV to elicit strong,
broad T cell responses is likely to be a determining factor
in their success.
We have recently reported that vaccines based on a com-
bination of the HIV-1 Tat protein with heterologous anti-
gens induce broader T cell responses against the co-
administered antigen, thereby indicating Tat as a useful
tool in the development of novel vaccination strategies
against AIDS [7-9].
As the HIV-1 Gag antigen is one of the most conserved
viral proteins, and is known to induce T cell responses,
both in animal models and in humans, it is widely con-
sidered a relevant antigen for the development of an anti-
HIV vaccine. Indeed, previous studies have shown that
Gag-specific T cell responses contribute to clear primary
viremia and control later viral replication, thereby slowing
progression of the disease [4,10-12].
Small animal models, in particular mice, represent a use-
ful tool for studying the dynamics of immune responses
induced after vaccination, although, the evaluation of cel-
lular responses induced by vaccination is usually
restricted to immunodominant T cell epitopes, which rep-
resent, only a minor part of the overall cellular immune
response. In order to expand our limited knowledge of
epitope-specific T cell responses directed to a given anti-
gen, the aim of this study was to identify the repertoire of
CD8+ T cell epitopes of the HIV-1 Gag antigen in BALB/c
mice vaccinated with the HIV-1 Gag protein.
Results and Discussion
In vivo modulation of epitope-specific T cell responses 
against the HIV-1 Gag antigen by the HIV-1 Tat protein
We recently demonstrated in BALB/c mice vaccinated with
the HIV-1 Gag protein [9] that Gag-specific T cell
responses are directed to 7 different peptides (peptides:
42, 49, 50, 53, 65, 75 and 76). Only two (49 and 50) of
these peptides were already known to contain the major
Kd-restricted CTL epitope (AMQ, aa 197–205), while pep-
tides 65 (aa 257–271) and 75 (aa 297–311) were known
to contain T cell epitopes which had not been fully char-
acterized [13,14].
In a previous study, we also showed that co-immuniza-
tion of mice with the HIV-1 Tat protein broadens the cel-
lular responses against Gag, as fresh splenocytes purified
from mice immunized with Gag and Tat responded to 12
different peptides (20, 21, 39, 42, 49, 50, 53, 65, 69, 75,
76 and 80), five more (20, 21, 39, 69 and 80) than those
reported in mice immunized with Gag alone, thereby sug-
gesting that Tat expands T cell responses directed to the
Gag antigen [9]. A summary of the previously detected T
cell responses directed to 15 amino acid long peptides is
reported in Figure 1.
Identification of new CD8+ T cell responses against the 
HIV-1 Gag antigen
To characterize peptide-specific CD8-mediated T cell
responses in mice vaccinated with Gag alone or with a
combination of Gag and Tat, CD8+ T cells were purified
from fresh splenocytes and tested by IFN-γ Elispot assays
using the previously identified peptides (Figure 1). As
shown in Figure 2A, the majority of peptides were found
to be targets of CD8+ T cells. Only peptides 39 and 75
failed to activate CD8+ cells, thereby confirming previous
results suggesting that peptides 39 and 75 contain two
CD4+ T cell epitopes [14].
To identify the minimal CD8 target epitopes, we then
used the peptide binding motif for Kd class I molecules
[15]. By this approach, 6 different potential epitopes
within the sequences of the responding 15 mers were
identified (Table 1). Eight to ten amino acid long peptides
were used to stimulate purified CD8+ cells and to perform
IFN-γ Elispot assays. As shown in Figure 2B, CD8+ T cell
responses were clearly directed to peptides LYC, MFS, IYK
and MYS, contained in 15 mers 21, 42, 65 and 69, respec-
tively. CD8-mediated T cell responses were also directed
to the previously described AMQ peptide [13], contained
within peptides 49 and 50. Remarkably, the results indi-
cate that peptide 65 contains not only a CD4+ T cell
epitope, as previously suggested [14], but also a CD8+ T
cell epitope, since purified CD8+ T cells clearly responded
to the IYK epitope contained within peptide 65.
Further characterization of the T cell responses directed to
the identified peptides was then carried out by 51Cr-
release cytotoxicity assays. To this end, splenocytes from
mice immunized with Gag and Tat or with Gag alone were
stimulated in vitro with the identified 15 amino acid long
peptides and assayed in cytotoxicity against P815 cells
pulsed with the corresponding 15 amino acid long pep-
tides or with the minimal CTL epitopes. As shown in Fig-
ure 3, peptide-stimulated T cell cultures specifically lysed
cells pulsed with LYC, MFS, AMQ, 53, IYK, MYS, 76 and
80. These results demonstrate that all peptide-specific
CD8+ T cells, except CD8+ T cells specific for peptide 20,
in addition to secrete IFN-γ are able to lyse peptide-pulsed
target cells.
Conclusion
In this study we have defined new CD8-mediated Gag-
specific T cell responses in BALB/c mice vaccinated with
the Gag protein alone or with the combination Tat/Gag,
which had previously been shown to be very efficient at
inducing Th1 responses directed to Gag [9]. We demon-
strated that 9 out of 11 peptides stimulating IFN-γ T cellPage 2 of 7
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CD8+ T cells efficiently lysed peptide-pulsed target cells.
Four peptides were also characterized as minimal CTL
epitopes.
Induction of HIV-1-specific CTL responses has become a
critical component in the design of recombinant subunit
vaccines aimed at controlling HIV infection, and these
CD8-restricted epitopes, which, with the exception of the
AMQ peptide, were all identified here for the first time,
should be exploited in preclinical models for a complete
evaluation of cellular responses induced by Gag-based
vaccines.
Methods
HIV-1 proteins
The biologically active HIV-1 Tat protein from the human
T lymphotropic virus type IIIB isolate (BH10 clone) was
Tat broadens T cell responses against HIV-1 GagFigu e 1
Tat broadens T cell responses against HIV-1 Gag. Mice were immunized with Gag alone, with Gag in combination with Tat pro-
tein, or with PBS alone. After 3 immunizations, fresh splenocytes were tested by IFNγ Elispot assay using 15 amino acid long 
peptides encompassing the entire Gag sequence. Positive responses to the indicated peptides are represented in the Figure.
Positive 
responses
Immunization
Gag peptides inducing IFN-? responses
0PBS
81-95
78-91 153-167
193-207
257-271
297-311
165-179 209-223
197-211
273-287
301-315
317-331
193-207
257-271
297-311
165-179 209-223
197-211 301-315
7Gag
12Gag + Tat
Table 1: Gag peptides and predicted CTL epitopes
Peptide 
number
Peptide Sequence aa Predicted 
CTL Epitope
aa Code
20 SLYNTVATLYCVHQR 78–91 LYNTVATL 78–85 LYN
21 TVATLYCVHQRIEVK 81–95 LYCVHQRI 85–92 LYC
39 NAWVKVVEEKAFSPE 153–167 CD4 epitope - -
42 SPEVIPMFSALSEGA 165–179 MFSALSEGA 171–179 MFS
49 GHQAAMQMLKETINE 193–207 AMQMLKET 197–205 AMQ
50 AMQMLKETINEEAAE 197–211 AMQMLKET 197–205 AMQ
53 AAEWDRLHPVHAGPI 209–223 Not identified - -
65 PVGEIYKRWIILGLN 257–271 IYKRWIILGL 261–270 IYK
69 IVRMYSPTSILDIRQ 273–287 MYSPTSILDI 276–285 MYS
75 VDRFYKTLRAEQASQ 297–311 CD4 epitope - -
76 YKTLRAEQASQEVKN 301–315 Not identified - -
80 MTETLLVQNANPDCK 317–331 Not identified - -Page 3 of 7
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Peptide-specific CD8+ T cell responses against the HIV-1 Gag antigen in mice immunized with Gag or with the combination Gag and TatFigur  2
Peptide-specific CD8+ T cell responses against the HIV-1 Gag antigen in mice immunized with Gag or with the combination 
Gag and Tat. After 3 immunizations, fresh splenocytes were pooled and purified, then CD8+ T cells were tested by IFNγ Elis-
pot assay after stimulation with the indicated 15 mers (panel A), or with the indicated 8–10 mers derived from the above 15 
mers (panel B). Results from mice immunized with Gag (empty bars) and from mice immunized with Gag and Tat (filled bars) 
are expressed as SFU ± SD/106 cells. The mean +/- SD of three independent experiments is shown.
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Virology Journal 2008, 5:81 http://www.virologyj.com/content/5/1/81expressed in E. Coli and purified by heparin-affinity chro-
matography and HPLC as previously described [16]. The
Tat protein was stored in lyophilized form at -80°C,
reconstituted in degassed buffer before use, and handled
as described to prevent oxidation and loss of biological
activity [17]. Different lots of Tat were used with repro-
ducible results, and in all cases endotoxin concentration
was undetectable (detection threshold: 0.05 EU/μg). HIV-
1 GagSF2 protein was obtained from the NIH AIDS Rea-
gent Program.
Peptides
Peptides were synthesized by the solid phase method and
purified by HPLC to >98% purity, as previously described
[18]. Structural verification was performed by elemental
and amino acid analysis and mass spectrometry. Gag pep-
tides, 15 amino acid long and overlapping by 10 to 11
amino acids, spanning the entire Gag (HIV-1 consensus
subtype B Gag complete set # 8117) sequence, were pro-
vided by the NIH AIDS Reagent Program. Peptides were
dissolved in DMSO at 10-3 M, kept at -20°C, and diluted
in PBS before use.
Immunization of mice
BALB/c mice (H-2d) (Harlan, Udine, Italy) were immu-
nized subcutaneously at a single site in the back with 5 μg
of HIV-1 Gag protein alone or in combination with 5 μg
of native monomeric biologically active Tat protein in Fre-
und's adjuvant [9]. Each group was composed of 5 ani-
mals. Immunogens were given subcutaneously in 100 μl
injections, on days 1, 14 and 28, and mice were sacrificed
10 days after the final boost (day 38). During the course
of the experiments, animals were checked twice a week at
the site of injection, as well as for their general conditions
(such as liveliness, food intake, vitality, weight, motility,
sheen of fur). No signs of local or systemic adverse reac-
tions were observed at any time in mice receiving the
immunogens, as compared to control or untreated mice.
Animal use was carried out according to European and
institutional guidelines.
Peptide-specific cytotoxic T cell responses against the HIV-1 Gag antigen in mice immunized with Gag or with the combination Gag and TatFigur  3
Peptide-specific cytotoxic T cell responses against the HIV-1 Gag antigen in mice immunized with Gag or with the combination 
Gag and Tat. Splenocytes from each group were re-stimulated in vitro with the indicated peptides. After 5 days, T cell cultures 
were tested against P815 cells (ratio 50:1) treated with the indicated peptides. Results from mice immunized with Gag (empty 
bars) and from mice immunized with Gag and Tat (filled bars) are expressed as % specific lysis calculated by subtracting the lysis 
of untreated P815 cells (always below 3%). The mean +/- SD of the results from three independent experiments, performed in 
triplicate, is shown.
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Splenocytes were purified from spleens squeezed onto fil-
ters (Becton Dickinson). Spleens of each experimental
group were pooled. Following red blood cell lysis, cells
were resuspended in RPMI 1640 supplemented with 10%
FBS (Gibco) and immediately used for the analysis of
antigen-specific cellular immune responses by cytotoxic-
ity or Elispot assays [9]. When indicated, splenocytes were
also stimulated in vitro with 1 μg/ml of peptide and tested
in cytotoxic assays after 5 days of culture. Purified CD8+ T
cells were obtained using the BD™ IMag Mouse Lym-
phocyte Enrichment Set-DM filters (Becton Dickinson),
according to the manufacturer's instructions. Purified cells
were stained with FITC-conjugated anti-mouse CD8 mAb
(Becton Dickinson). Flow cytometry analysis was per-
formed with a FACScan (Becton Dickinson), and CD8-
positive cells were > 90% in all cases.
Cytotoxicity assay
P815 target cells were labeled with Na251CrO4 for 90 min
at 37°C. Cytotoxicity tests were routinely run in triplicate
at different effector:target ratios [18]. Percent specific lysis
was calculated as 100× (cpm sample - cpm medium)/
(cpm Triton X-100 - cpm medium). Spontaneous release
was always less than 20%.
Elispot assay
Elispot (IFN-γ) was carried out using commercially avail-
able kits provided by Becton Dickinson, according to the
manufacturer's instructions. Briefly, 96-well nitrocellu-
lose plates were coated with 5 μg/ml of anti-IFN-γ over-
night at 4°C [9]. The following day, the plates were
washed 4 times with PBS and blocked with RPMI 1640
supplemented with 10% FBS for 2 hours at 37°C. Splen-
ocytes (2.5 × 105/200 μl) were added to the wells (dupli-
cate wells) and incubated with peptides (10-6 M) for 16
hours at 37°C. Controls were represented by cells incu-
bated with Concanavaline A (Sigma; 5 μg/ml) (positive
control) or with medium alone (negative control). The
spots were read using an Elispot reader (Aelvis, Germany).
Responses at least 3 times higher than the mean number
of spots in the control wells and ≥ 50 spots/well/106 cells
were defined as positive. Results are expressed as net
number of spot forming units (SFU)/106 cells: [mean
number SFU of peptide treated wells minus mean number
SFU of the negative control].
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